Anacor has entered into partnership and works with UCSF to discover new antimalarial agents.
Anacor discovers, develops small-molecule therapeutics derived from its boron chemistry platform.
In addition Anacor works with Medicines for Malaria Venture (MMV) and has developed AN3661, a boron-based antimalarial compound that is currently in preclinical trials, and a funded research program to discover backup compounds for AN3661.
Anacor and MMV plan to conduct Phase 1 and Phase 2 proof of concept studies for AN3661, at which point GSK will have the option to license the program.